查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854806

伴侶動物疫苗市場（依動物種類、疫苗類型、給藥途徑及通路分類）－全球預測，2025-2032年

Companion Animal Vaccine Market by Animal Type, Vaccine Type, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，伴侶動物疫苗市場規模將達到 95.4 億美元，複合年成長率為 8.47%。

關鍵市場統計數據
基準年 2024 49.7億美元
預計年份：2025年 53.9億美元
預測年份 2032 95.4億美元
複合年成長率 (%) 8.47%

全面介紹不斷發展的伴侶動物疫苗領域：科學創新與飼主期望和臨床實踐的轉變相融合

伴侶動物疫苗領域正處於科學進步、飼主不斷變化的需求以及不斷發展的臨床實踐的交匯點。如今，預防保健理念和治療方法創新共同塑造犬貓疫苗接種策略，並影響診所的工作流程和供應鏈動態。獸醫相關人員擴大將診斷篩檢、個人化疫苗通訊協定和基於風險的建議融入日常工作中，這迫使生產商和經銷商重新思考產品系列和溝通策略。

隨著消費者對動物健康的意識不斷增強，寵物飼主對疫苗安全性和效用的要求也越來越高，他們需要更明確的證據。同時，數位化管道加速了人們獲取教育內容和購買管道的進程。此外，mRNA和重組系統等平台技術的研究突破正在拓展抗原標靶的範圍，並提升疫苗的免疫抗原性和生產效率。這些發展迫使疫苗生產商在現有去活化疫苗和減毒活病毒疫苗的基礎上，增加對新一代疫苗的投資。

此外，給藥途徑和分銷環境也會影響產品設計和商業策略。鼻腔和口腔黏膜疫苗的接受度與肌肉注射和皮下注射疫苗有所不同，而包括網路藥局和生產商網站在內的線上管道正在改變消費者的購買行為。這些動態共同要求產品開發、監管策略和市場開發採取整合策略，使科學機會與實際應用路徑相符。

本文詳細概述了影響伴侶動物疫苗研發、交付和推廣應用的主要技術、行為和臨床變化。

伴侶動物疫苗領域正經歷著變革性的轉變，其驅動力包括技術創新、消費者行為的改變以及監管和臨床模式的演進。疫苗平台（尤其是mRNA和重組技術）的開發，開啟了新的可能性，包括靶向免疫策略、更短的研發週期以及可適應新出現的疾病威脅的生產過程。這些科學進步正在重新定義產品藍圖，並迫使現有製造商重新評估其研發重點和策略夥伴關係。

同時，數位化互動的作用持續擴大。寵物飼主現在可以透過線上平台獲取獸醫資訊、做出購買決策並尋求遠距健康諮詢，這推動了網路藥局和廠商直銷管道的興起。這種轉變迫使各利益相關者制定整合的全通路策略，將教育推廣、透明的療效和安全性數據以及簡化的購買體驗相結合，以建立信任並促進相關人員按時接種疫苗。

此外，社會對寵物預防保健態度的轉變以及人們對便利性和個人化照護日益成長的期望正在重塑臨床實踐。獸醫們擴大採用基於風險的疫苗通訊協定，利用診斷工具為每隻動物量身定做疫苗接種計劃，最佳化依從性，並優先選擇能最大限度減少不利事件的疫苗類型和接種途徑。這些因素共同推動了疫苗研發、分發和推薦方式的根本性轉變，為價值鏈上的創新者和服務供應商帶來了挑戰和機會。

對2025年美國關稅對疫苗供應鏈、生產決策和商業通路經濟的累積影響進行全面分析

2025年，美國加徵的關稅增加了伴侶動物疫苗生態系統中製造商、經銷商和臨床終端用戶的複雜性。這些關稅影響了進口原料、成品疫苗、專用設備等的成本結構，改變了供應鏈決策，並促使企業重新評估生產佈局。一些相關人員加快了近岸外包，並實現了供應商組合多元化，以降低貿易相關成本波動帶來的風險；而另一些利害關係人則尋求合約對沖，以確保關鍵投入品的供應。

這些貿易政策調整也影響了各通路的商業規劃和定價策略。從國際管道採購疫苗的獸醫院和診所調整了採購週期和供應商條款，以維持可預測的存量基準。線上藥局和直接面向製造商的管道則調整了採購組合和物流安排，以確保寵物飼主的收貨時間和服務水準。同時，監管合規和海關管制在產品上市和跨境分銷的討論中也變得更加重要。

此外，關稅引發的供應鏈重組促使人們重新關注國內製造能力和官民合作關係，以增強生物製造的韌性。投資者和策略領導者正在權衡建立國內生產能力的益處與相關的資本需求和時限，優先考慮能夠靈活調整生產規模的技術。總而言之，這些調整反映了整個行業更廣泛的迫切需求，即增強供應鏈的穩健性，減少對單一供應商的依賴，並使商業模式適應日益加劇的貿易不確定性環境。

可操作的細分市場情報，揭示產品類型、疫苗平台、給藥途徑和分銷管道如何相互交織，從而塑造產品和商業化策略。

細分市場分析揭示了需求促進因素、臨床偏好和管道行為如何因物種、疫苗平台、給藥途徑和通路而異。就動物物種而言，貓和狗的流行病學和飼養方式存在差異，這會影響疫苗的優先順序、接種計劃和飼主的諮詢。犬類疫苗接種策略通常著重於與戶外活動和社交互動相關的核心疫苗和生活方式疫苗，而貓的通訊協定則優先考慮與室內/室外環境和多寵物家庭相關的疾病風險。

從疫苗類型來看，去活化疫苗和減毒活病毒疫苗仍然是多種適應症的常用疫苗，其中去活化疫苗進一步細分為裂解細胞和全細胞疫苗，這些差異會影響免疫抗原性和反應原性。 mRNA疫苗和重組疫苗等新型疫苗為更精準地靶向疾病和設計抗原結構提供了契機，從而最佳化免疫反應並減少不利事件。次單位疫苗疫苗和類毒素疫苗在對抗某些病原體方面仍然發揮著重要作用，因為在這些情況下，目標抗原呈現或毒素中和至關重要。

給藥途徑是另一個關鍵的差異化因素，鼻腔或口服黏膜給藥方式為腸外肌肉注射或皮下注射提供了一種非侵入性替代方案，並可實現獨特的免疫學特性。傳統的實體管道，例如藥局、獸醫診所和動物醫院，以及由網路藥局和製造商網站組成的線上管道，都呈現出不同的客戶觸點和監管考量。了解這些細分維度如何相互交織，對於設計符合相關人員期望和業務實際情況的產品系列、臨床指南和通路策略至關重要。

區域策略洞察，揭示不同管理體制、獸醫基礎設施和飼主行為如何驅動全球市場採取差異化策略

美洲、歐洲、中東和非洲以及亞太地區的區域動態對臨床實務規範、法律規範和商業性模式有顯著影響。在美洲，獸醫基礎設施和飼主參與模式支持多元化的分銷管道，強大的診所網路和日益普及的數位化應用增強了預防保健解決方案的推廣和零售。相較之下，歐洲、中東和非洲的法規環境和經濟狀況呈現出複雜多變的特點，因此需要高度區域化的監管策略和靈活的分銷模式，以滿足已開發獸醫市場和新興細分市場的需求。

亞太地區既快速接受技術創新，又面臨獸醫服務可近性參差不齊的問題。主要市場的都市化和寵物擁有率的上升推動了對最新疫苗技術的需求，而物流因素和區域供應鏈則影響產品的供應。在所有地區，對伴侶動物的文化態度、公共衛生重點以及獸醫訓練標準都會影響疫苗接種通訊協定的建議和接受程度。這些區域差異要求制定打入市場策略、提供針對特定區域的臨床證據，並進行能夠引起獸醫和飼主共鳴的精準宣傳宣傳活動。

最終，有效的區域規劃將流行病學見解與現實的供應和分銷模式、監管指導以及相關人員參與相結合，以確保疫苗創新能夠以正確的支援材料和服務模式到達正確的市場。

深入的競爭格局和生態系統評估，揭示現有企業、生物技術創新者和服務提供者如何塑造技術採納和商業化策略。

伴侶動物疫苗市場由成熟的生產者、專業的生技公司和新興創新者組成。現有企業繼續利用其廣泛的商業性佈局、與獸醫專業人士的長期合作關係以及涵蓋傳統疫苗平台的豐富產品系列。這些優勢有助於擴大規模、提升分銷信譽、累積深厚的臨床經驗，並使其能夠與獸醫網路和機構投資者保持持續的合作關係。

同時，專業公司和生物技術參與企業正專注於平台創新，瞄準高價值適應症，並利用重組抗原和mRNA構建等技術，透過療效、安全性和上市速度脫穎而出。這些企業通常尋求與受託製造廠商和學術機構建立策略聯盟，以加速研發並最佳化資本配置。大型製造商與靈活創新者之間的夥伴關係日益普遍，有助於將商業性影響力與科學新穎性結合。

價值鏈上的服務供應商，包括契約製造、診斷公司和數位健康平台，在產品開發、品質保證和客戶參與方面發揮關鍵作用。可擴展的生產能力、低溫運輸物流和數據驅動型行銷等能力，正協助將科學進步轉化為臨床應用的產品。總體而言，競爭格局有利於那些兼具科學差異化、穩健的生產能力以及對獸醫實踐動態的深刻理解的公司，從而實現產品在臨床醫生和飼主中的持續應用。

為領導者提供清晰、優先的策略建議，重點在於平台多元化、供應鏈彈性、通路最佳化和臨床證據產生。

產業領導者應圍繞四個相互關聯的行動調整其策略重點：投資平台多元化、增強供應鏈韌性、最佳化通路策略以及深化臨床合作。優先採用投資組合策略，平衡對成熟的去活化和減毒活產品以及mRNA、重組、次單元和類毒素技術的投資，將使企業能夠同時滿足當前的臨床需求和應對未來的疾病威脅。此外，選擇擴充性的生產合作夥伴並考慮區域生產能力，可以降低貿易中斷帶來的風險，並有助於加快產品上市速度。

同樣重要的是改進分銷策略，以適應不斷變化的消費者行為。除了加強線上通路（例如網路藥局和廠商直銷平台）外，還應加強與藥局、獸醫診所和醫院的合作關係，以確保臨床應用和治療的連續性。此外，針對不同給藥途徑（無論是黏膜給藥或腸外給藥）調整訊息，並提供可靠的臨床證據，可以提高獸醫的信心和飼主的接受度。

最後，領導者應投資於有針對性的臨床教育和真實世界證據，以支持差異化的產品定位，並為基於風險的疫苗接種通訊協定提供資訊。落實這些建議需要研發、監管、商業和供應鏈團隊之間的協作，才能將策略意圖轉化為可衡量的應用成果。

採用穩健的混合調查方法，結合主要相關人員訪談、二手證據綜合和交叉檢驗，確保得出可操作且可靠的研究結果。

本報告的調查方法結合了質性訪談、文獻綜述和嚴格的交叉檢驗，以確保分析的平衡性和可靠性。主要見解來自對獸醫從業人員、行業高管、研發負責人和分銷專家的結構化訪談，從而對臨床應用、產品偏好和物流挑戰有了切實的觀點。這些定性資訊與監管指南、同行評審的科學文獻和公開的行業報告等二手資料相結合，為技術和市場趨勢提供了背景資訊。

為了提高可靠性，研究結果在多個相關人員群體和地區進行交叉檢驗，特別關注已開發市場和新興市場臨床實踐模式的差異。這種方法強調假設的透明度、資料來源的清晰記錄以及對原始研究倫理標準的遵守。分析方法包括趨勢圖譜繪製、技術成熟度評估和通路路徑分析，旨在揭示商業化影響以及相關人員的策略選擇。

此調查方法確保研究結果不僅說明，而且具有可操作性，為決策者評估伴侶動物疫苗領域的創新機會、分銷選擇和投資重點提供了堅實的基礎。

簡明扼要地總結了決定伴侶動物疫苗領域策略成果的技術、商業性和區域性因素。

本執行摘要總結了影響伴侶動物疫苗發展的關鍵動態，重點闡述了科學創新、不斷變化的飼主期望、不斷演變的配銷通路以及地緣政治供應因素之間的相互作用。 mRNA和重組疫苗等技術的成熟，以及去活化疫苗、減毒活病毒疫苗、次單元和類毒素疫苗等傳統疫苗平台的持續應用，為研發人員提供了更廣泛的選擇，以滿足尚未滿足的臨床需求並提高疫苗的安全性。同時，給藥途徑偏好和分銷管道行為的轉變，也要求制定協調一致的策略，以確保疫苗的臨床應用和病人遵從性。

此外，美洲、歐洲、中東和非洲以及亞太地區的區域差異凸顯了與區域監管機構溝通以及採取符合當地文化的策略的重要性。貿易政策調整的累積影響凸顯了供應鏈敏捷性的必要性以及投資區域製造能力的潛力。能夠將科學差異化與商業性規模、穩健的業務營運以及與獸醫網路和數位管道的深度夥伴關係相結合的企業，將在競爭中脫穎而出。

總之，積極協調研發、生產和商業策略，並投資於臨床證據和通路整合的相關人員，將最有能力將創新轉化為改善動物健康結果和永續的業務績效。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • mRNA和下一代疫苗平台在犬貓領域的應用日益廣泛
  • 針對多種犬類疾病的聯合疫苗的需求日益成長，提高了疫苗的覆蓋率。
  • 疫苗輸送系統的技術進步，例如無針注射器和貼片；
  • 監管協調和加速核准將加快新型寵物疫苗進入市場的速度。
  • 根據每隻寵物的遺傳和生活方式因素制定個人化疫苗接種方案的重要性日益凸顯。
  • 擴大輔助性治療，以提高伴侶動物疫苗的有效性
  • 整合數位健康監測和遠端醫療平台以提高疫苗接種率
  • 人們越來越關注疫苗相關不利事件，這推動了更安全佐劑和製劑的研發。
  • 生技公司與獸醫診所建立策略夥伴關係，加速疫苗開發平臺
  • 新興市場獸醫診所網路的全球擴張提高了動物疫苗的可及性。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 伴侶動物疫苗市場（依動物種類分類）

  • 貓
  • 狗

9. 伴侶動物疫苗市場（依疫苗類型分類）

  • 惰性
    • 裂解疫苗
    • 全顆粒疫苗
  • 活病毒疫苗
  • mRNA
  • 重組
  • 次單元
  • 類毒素

10. 伴侶動物疫苗市場依給藥途徑分類

  • 黏膜
    • 鼻腔
    • 口服
  • 腸外
    • 肌肉內注射
    • 皮下

11. 伴侶動物疫苗市場依通路分類

  • 線上
    • 電子藥房
    • 製造商網站
  • 藥局
  • 獸醫診所
  • 獸醫診所

12. 各地區伴侶動物疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 伴侶動物疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國伴侶動物疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Elanco Animal Health Incorporated
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Laboratorios Hipra, SA
    • Animalcare Group PLC
    • Esco Healthcare
Product Code: MRR-957C47F94D1F

The Companion Animal Vaccine Market is projected to grow by USD 9.54 billion at a CAGR of 8.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.97 billion
Estimated Year [2025] USD 5.39 billion
Forecast Year [2032] USD 9.54 billion
CAGR (%) 8.47%

Comprehensive introduction to the evolving companion animal vaccine environment where scientific innovation converges with owner expectations and clinical practice shifts

The companion animal vaccine landscape sits at an intersection of scientific advancement, shifting owner expectations, and evolving clinical practice. Contemporary stakeholders operate in an environment where both preventive care philosophy and therapeutic innovation shape vaccination strategies for cats and dogs, influencing clinic workflows and supply chain dynamics. Veterinary professionals increasingly integrate diagnostic screening, individualized vaccine protocols, and risk-based recommendations into routine care, prompting manufacturers and distributors to reassess product portfolios and communication tactics.

As consumer awareness of animal health grows, pet owners demand clearer evidence of vaccine safety and benefit, while digital channels accelerate access to educational content and purchasing options. Concurrently, research breakthroughs in platform technologies such as mRNA and recombinant systems are expanding the range of antigen targets and enabling improved immunogenicity and manufacturing efficiencies. These developments prompt manufacturers to balance legacy product support for inactivated and live attenuated vaccines with investment in next-generation modalities.

In addition, the route of administration and the distribution landscape influence both product design and commercial strategy. Mucosal vaccines administered nasally or orally present different acceptance profiles compared with parenteral intramuscular or subcutaneous injections, and online channels including e-pharmacies and manufacturer websites are transforming procurement behaviors. Taken together, these dynamics require an integrated approach to product development, regulatory strategy, and market engagement that aligns scientific opportunity with practical adoption pathways.

In-depth overview of the major technological, behavioral, and clinical shifts reshaping how companion animal vaccines are developed, delivered, and adopted

The companion animal vaccine sector is undergoing transformative shifts driven by technological innovation, changing consumer behaviors, and evolving regulatory and clinical paradigms. Advances in vaccine platforms, notably mRNA and recombinant technologies, are opening new possibilities for targeted immunization strategies, shorter development cycles, and adaptable manufacturing processes capable of responding to emergent disease threats. These scientific advancements are redefining product roadmaps and prompting incumbent manufacturers to re-evaluate R&D priorities and strategic partnerships.

Simultaneously, the role of digital engagement continues to expand. Pet owners now access veterinary information, make purchasing decisions, and seek telehealth consultations through online portals, influencing the prominence of e-pharmacies and manufacturer direct-sales channels. This shift compels stakeholders to develop integrated omni-channel strategies that combine educational outreach, transparent efficacy and safety data, and streamlined purchasing experiences to build trust and foster adherence to vaccination schedules.

Moreover, changing societal views on preventive healthcare for pets and rising expectations around convenience and individualized care are reshaping clinical practice. Veterinarians are increasingly employing risk-based vaccination protocols, leveraging diagnostic tools to tailor immunization plans for individual animals, and prioritizing vaccine types and routes that optimize compliance and minimize adverse events. Together, these factors constitute a structural shift in how vaccines are developed, distributed, and recommended, creating both challenges and opportunities for innovators and service providers across the value chain.

Comprehensive analysis of the cumulative repercussions of United States tariff measures in 2025 on supply chains, manufacturing decisions, and commercial channel economics for companion vaccines

In 2025, tariff measures implemented by the United States introduced an added layer of complexity for manufacturers, distributors, and clinical end users within the companion animal vaccine ecosystem. Tariffs influence cost structures across imported raw materials, finished vaccines, and specialized equipment, thereby altering supply chain decisions and encouraging re-evaluation of manufacturing footprints. Some stakeholders accelerated nearshoring and diversified supplier portfolios to mitigate exposure to trade-related cost volatility, while others sought contractual hedges that preserved access to critical inputs.

These trade policy adjustments also impacted commercial planning and pricing strategies across distribution channels. Veterinary hospitals and clinics that source vaccines internationally reevaluated procurement cycles and supplier terms to maintain predictable inventory levels. Online pharmacies and manufacturer direct channels responded by adjusting their sourcing mixes and logistics arrangements to sustain delivery timelines and service levels to pet owners. In parallel, regulatory compliance and customs administration became more salient considerations during product launches and cross-border distribution discussions.

Furthermore, the tariff-driven recalibration of supply chains prompted renewed attention to domestic manufacturing capabilities and public-private partnerships that support biomanufacturing resilience. Investors and strategic leaders began to weigh the benefits of building local capacity against the capital requirements and timeframes involved, prioritizing technologies that offer flexible production scales. Collectively, these adjustments reflect a broader industry imperative to enhance supply chain robustness, reduce single-source dependencies, and align commercial models with an environment of elevated trade uncertainty.

Actionable segmentation intelligence illuminating how animal type, vaccine platform, administration route, and distribution channel intersect to shape product and commercialization strategies

Segmentation insights reveal how demand drivers, clinical preferences, and channel behaviors vary across animal type, vaccine platform, administration route, and distribution pathways. When considering animal type, cats and dogs display distinct epidemiological and husbandry profiles that shape vaccine prioritization, dosing schedules, and owner counseling. Vaccination strategies for dogs often emphasize core and lifestyle vaccines aligned with outdoor exposure and social interactions, whereas feline protocols prioritize disease risks aligned with indoor/outdoor status and multi-cat household dynamics.

Diving into vaccine type, inactivated platforms and live attenuated vaccines remain well-established for a variety of indications, with inactivated formulations further differentiated into split cell and whole cell options that influence immunogenicity and reactogenicity considerations. Emerging modalities such as mRNA and recombinant vaccines are creating opportunities to target diseases with greater precision and to design antigen constructs that optimize immune response while potentially reducing adverse events. Subunit and toxoid vaccines continue to play critical roles for specific pathogens where targeted antigen presentation or neutralization of toxins is essential.

Route of administration is another vital differentiator, with mucosal options delivered nasally or orally offering non-invasive alternatives to parenteral intramuscular and subcutaneous injections and enabling unique immunological profiles. Distribution channel dynamics further influence access and adoption; online channels comprised of e-pharmacies and manufacturer websites, along with more traditional outlets such as pharmacies, veterinary clinics, and veterinary hospitals, present differing customer journeys and regulatory considerations. Understanding how these segmentation axes intersect is essential for designing product portfolios, clinical guidance, and channel strategies that align with stakeholder expectations and operational realities.

Strategic regional insights into how diverse regulatory regimes, veterinary infrastructures, and owner behaviors drive differentiated approaches across global markets

Regional dynamics significantly influence clinical practice norms, regulatory frameworks, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, veterinary care infrastructure and owner engagement models support diverse distribution channels, with strong clinic networks and growing digital adoption that enhances outreach and retailing of preventive healthcare solutions. In contrast, Europe, Middle East & Africa exhibits a mosaic of regulatory environments and economic contexts, requiring highly localized regulatory strategies and flexible distribution models that accommodate both advanced veterinary markets and emerging segments.

Asia-Pacific presents a mix of rapid innovation adoption and variable access to veterinary services, where urbanization and rising pet ownership in key markets drive demand for modern vaccine technologies while logistical considerations and regional supply chains influence product availability. Across all regions, cultural attitudes toward companion animals, public health priorities, and veterinary training standards shape how vaccination protocols are recommended and accepted. These regional nuances necessitate tailored market entry strategies, localized clinical evidence packages, and targeted communication campaigns that resonate with veterinarians and pet owners alike.

Ultimately, effective regional planning integrates epidemiological insight with pragmatic supply and distribution models, regulatory navigation, and stakeholder engagement to ensure that vaccine innovations reach the right markets with appropriate supporting materials and service models.

Deep competitive and ecosystem assessment revealing how incumbents, biotech innovators, and service providers shape adoption and commercialization strategies

Competitive dynamics in the companion animal vaccine sector reflect a blend of established incumbents, specialist biotech firms, and emerging innovators. Established manufacturers continue to leverage broad commercial footprints, long-standing relationships with veterinary professionals, and extensive product portfolios that span traditional vaccine platforms. These capabilities support scale, distribution reliability, and deep clinical familiarity, enabling sustained engagement with veterinary networks and institutional buyers.

At the same time, specialist companies and biotech entrants focus on platform innovation, targeting high-value indications and leveraging technologies such as recombinant antigens and mRNA constructs to differentiate on efficacy, safety, and speed-to-market. These players often pursue strategic collaborations with contract manufacturing organizations and academic groups to accelerate development while optimizing capital allocation. Partnerships between large-scale manufacturers and nimble innovators are increasingly common, facilitating combination strategies that pair commercial reach with scientific novelty.

Service providers across the value chain, including contract manufacturers, diagnostic firms, and digital health platforms, play a pivotal role in enabling product development, quality assurance, and customer engagement. Their capabilities in scalable manufacturing, cold chain logistics, and data-driven marketing help translate scientific advances into clinically adopted products. Overall, the competitive landscape favors organizations that combine scientific differentiation, manufacturing resilience, and a deep understanding of veterinary practice dynamics to achieve sustained adoption among clinicians and pet owners.

Clear and prioritized strategic recommendations for leaders focused on platform diversification, supply resilience, channel optimization, and clinical evidence generation

Industry leaders should align strategic priorities around four interconnected actions: invest in platform diversification, fortify supply chain resilience, optimize channel strategies, and deepen clinical engagement. Prioritizing a portfolio approach that balances established inactivated and live attenuated products with investments in mRNA, recombinant, subunit, and toxoid technologies will allow organizations to respond to both current clinical needs and future disease threats. Concurrently, selecting scalable manufacturing partners and considering regional production capabilities can reduce exposure to trade disruptions and support faster market responsiveness.

Equally important is the refinement of distribution strategies to reflect evolving purchaser behaviors. Strengthening digital channels such as e-pharmacies and manufacturer direct-sales platforms should be complemented by reinforced relationships with pharmacies, veterinary clinics, and hospitals to ensure clinical adoption and continuity of care. In addition, tailoring messaging to emphasize route-of-administration benefits, whether mucosal or parenteral, and providing robust clinical evidence will improve veterinarian confidence and owner acceptance.

Finally, leaders should invest in targeted clinical education and real-world evidence generation that supports differentiated product positioning and informs risk-based vaccination protocols. Executing these recommendations requires cross-functional coordination across R&D, regulatory, commercial, and supply chain teams to translate strategic intent into measurable adoption outcomes.

Robust mixed-method methodology combining primary stakeholder interviews, secondary evidence synthesis, and cross-validation to ensure actionable and credible insights

The research methodology underpinning this report combines primary qualitative interviews, secondary literature synthesis, and rigorous cross-validation to ensure balanced analysis and credibility. Primary insights were obtained through structured interviews with veterinary practitioners, senior industry executives, R&D leaders, and distribution specialists, providing grounded perspectives on clinical adoption, product preferences, and logistical challenges. These qualitative inputs were synthesized with secondary sources that include regulatory guidance, peer-reviewed scientific literature, and publicly available industry reports to contextualize technological and market trends.

To enhance reliability, findings were cross-validated across multiple stakeholder groups and geographic contexts, with particular attention to differences in clinical practice patterns between developed and emerging veterinary markets. The approach emphasizes transparency in assumptions, clear documentation of data provenance, and adherence to ethical standards in primary research engagements. Analytical methods include trend mapping, technology readiness assessment, and channel pathway analysis to illuminate commercialization implications and strategic options for stakeholders.

This methodology ensures that insights are not only descriptive but also actionable, offering decision-makers a robust foundation to evaluate innovation opportunities, distribution choices, and investment priorities within the companion animal vaccine landscape.

Concise conclusion synthesizing technological, commercial, and regional imperatives that determine strategic outcomes in the companion animal vaccine sector

This executive summary synthesizes the essential dynamics shaping companion animal vaccines, underscoring the interplay of scientific innovation, changing owner expectations, distribution evolution, and geopolitical supply considerations. The maturation of technologies such as mRNA and recombinant vaccines, coupled with enduring roles for inactivated, live attenuated, subunit, and toxoid platforms, provides a broad palette for developers to address unmet clinical needs and improve safety profiles. Parallel shifts in route-of-administration preferences and distribution channel behaviors require coordinated strategies to ensure clinical adoption and owner adherence.

Moreover, regional differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific emphasize the importance of localized regulatory navigation and culturally attuned engagement. The cumulative impact of trade policy adjustments highlighted the need for supply chain agility and potential investments in regional manufacturing capabilities. Competitive success will favor organizations that can blend scientific differentiation with commercial scale, resilient operations, and deep partnerships across veterinary networks and digital channels.

In conclusion, stakeholders that proactively align R&D, manufacturing, and commercial strategies while investing in clinical evidence and channel integration will be best positioned to translate innovation into improved animal health outcomes and sustainable business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of mRNA and next-generation vaccine platforms for dogs and cats
  • 5.2. Increasing demand for combination vaccines targeting multiple canine diseases to improve coverage
  • 5.3. Technological advancements in vaccine delivery systems such as needle-free injectors and patches
  • 5.4. Regulatory harmonization and fast-track approvals enabling quicker market entry for novel pet vaccines
  • 5.5. Growing emphasis on personalized vaccination schedules based on individual pet genetics and lifestyle factors
  • 5.6. Expansion of probiotic and immunomodulator adjunct therapies to enhance vaccine efficacy in companion animals
  • 5.7. Integration of digital health monitoring and telemedicine platforms to boost vaccine compliance rates
  • 5.8. Rising concerns over vaccine-associated adverse events driving development of safer adjuvants and formulations
  • 5.9. Strategic collaborations between biotech firms and veterinary clinics to accelerate vaccine R&D pipelines
  • 5.10. Global expansion of veterinary clinic networks in emerging markets increasing access to animal vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Vaccine Market, by Animal Type

  • 8.1. Cats
  • 8.2. Dogs

9. Companion Animal Vaccine Market, by Vaccine Type

  • 9.1. Inactivated
    • 9.1.1. Split Cell
    • 9.1.2. Whole Cell
  • 9.2. Live Attenuated
  • 9.3. mRNA
  • 9.4. Recombinant
  • 9.5. Subunit
  • 9.6. Toxoid

10. Companion Animal Vaccine Market, by Route Of Administration

  • 10.1. Mucosal
    • 10.1.1. Nasal
    • 10.1.2. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Subcutaneous

11. Companion Animal Vaccine Market, by Distribution Channel

  • 11.1. Online
    • 11.1.1. E Pharmacies
    • 11.1.2. Manufacturer Websites
  • 11.2. Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Companion Animal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Elanco Animal Health Incorporated
    • 15.3.4. Boehringer Ingelheim International GmbH
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Vetoquinol S.A.
    • 15.3.8. Dechra Pharmaceuticals PLC
    • 15.3.9. Laboratorios Hipra, S.A.
    • 15.3.10. Animalcare Group PLC
    • 15.3.11. Esco Healthcare

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COMPANION ANIMAL VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COMPANION ANIMAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION ANIMAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 319. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GCC COM